Shnyder SD - Search Results

1

Tumor growth suppression using a combination of taxol-based therapy and GSK3 inhibition in non-small cell lung cancer.

O'Flaherty L, Shnyder SD, Cooper PA, Cross SJ, Wakefield JG, Pardo OE, Seckl MJ, Tavaré JM. O'Flaherty L, et al. Among authors: shnyder sd. PLoS One. 2019 Apr 10;14(4):e0214610. doi: 10.1371/journal.pone.0214610. eCollection 2019. PLoS One. 2019. PMID: 30969984 Free PMC article.

2

Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours.

Holwell SE, Cooper PA, Grosios K, Lippert JW 3rd, Pettit GR, Shnyder SD, Bibby MC. Holwell SE, et al. Among authors: shnyder sd. Anticancer Res. 2002 Mar-Apr;22(2A):707-11. Anticancer Res. 2002. PMID: 12017147

3

Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model.

Shnyder SD, Cooper PA, Pettit GR, Lippert JW 3rd, Bibby MC. Shnyder SD, et al. Anticancer Res. 2003 Mar-Apr;23(2B):1619-23. Anticancer Res. 2003. PMID: 12820431

4

Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.

Kirwan IG, Loadman PM, Swaine DJ, Anthoney DA, Pettit GR, Lippert JW 3rd, Shnyder SD, Cooper PA, Bibby MC. Kirwan IG, et al. Among authors: shnyder sd. Clin Cancer Res. 2004 Feb 15;10(4):1446-53. doi: 10.1158/1078-0432.ccr-0518-03. Clin Cancer Res. 2004. PMID: 14977848

5

Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in a transplantable murine adenocarcinoma model.

Shnyder SD, Cooper PA, Gyselinck N, Hill BT, Double JA, Bibby MC. Shnyder SD, et al. Anticancer Res. 2003 Nov-Dec;23(6C):4815-20. Anticancer Res. 2003. PMID: 14981930

6

Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.

Wilkinson GP, Taylor JP, Shnyder S, Cooper P, Howard PW, Thurston DE, Jenkins TC, Loadman PM. Wilkinson GP, et al. Invest New Drugs. 2004 Aug;22(3):231-40. doi: 10.1023/B:DRUG.0000026249.97007.60. Invest New Drugs. 2004. PMID: 15122070

7

Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs.

Phillips RM, Jaffar M, Maitland DJ, Loadman PM, Shnyder SD, Steans G, Cooper PA, Race A, Patterson AV, Stratford IJ. Phillips RM, et al. Among authors: shnyder sd. Biochem Pharmacol. 2004 Dec 1;68(11):2107-16. doi: 10.1016/j.bcp.2004.08.007. Biochem Pharmacol. 2004. PMID: 15498501

8

Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.

Shnyder SD, Hasan J, Cooper PA, Pilarinou E, Jubb E, Jayson GC, Bibby MC. Shnyder SD, et al. Anticancer Res. 2005 May-Jun;25(3B):1889-94. Anticancer Res. 2005. PMID: 16158922 Free article.

9

Reducing the cost of screening novel agents using the hollow fibre assay.

Shnyder SD, Cooper PA, Scally AJ, Bibby MC. Shnyder SD, et al. Anticancer Res. 2006 May-Jun;26(3A):2049-52. Anticancer Res. 2006. PMID: 16827143 Free article.

10

The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.

Suggitt M, Cooper PA, Shnyder SD, Bibby MC. Suggitt M, et al. Among authors: shnyder sd. Int J Oncol. 2006 Dec;29(6):1493-9. Int J Oncol. 2006. PMID: 17088988

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

79 results

Search Page

Filters